Ikeda S, Esumi H, Suzuki T, Tomita Y
Gan No Rinsho. 1985 Jul;31(9 Suppl):1079-87.
Prognosis was obviously poor in PPSM-treated stage Ib cases, compared with extra PPSM-treated counterparts (P less than 0.01). Out of the PPSM-treated stage Ib cases, those where prophylactic lymph node dissection was performed ran a prognosis similar to the extra PPSM-treated stage Ib cases: it is advisable therefore to perform the prophylactic lymph node dissection actively in the PPSM-treated stage Ib cases. A response rate of 28.6% was achieved with PAV therapy in stage IV cases, with metastases to the skin, subcutaneous tissue, lymph nodes and bone responding to the therapy. PAV therapy, when applied in operable cases, brought about excellent 5-year survival rates as 100% high as in stage Ia, 92.9% in stage Ib, 53.1% in stage II, and 66.9% in stage Ib + II cases. In a randomized, controlled study of bestatin in stage Ib and II cases over about 4 years has revealed that both the disease-free rate and the survival rate were significantly high in the bestatin-treated group, compared with the control group.
与未接受胸膜肺切除术（PPSM）治疗的Ib期病例相比，接受PPSM治疗的Ib期病例预后明显较差（P<0.01）。在接受PPSM治疗的Ib期病例中，接受预防性淋巴结清扫术的患者预后与未接受PPSM治疗的Ib期病例相似：因此，建议在接受PPSM治疗的Ib期病例中积极进行预防性淋巴结清扫术。IV期病例采用PAV疗法的缓解率为28.6%，皮肤、皮下组织、淋巴结和骨转移对该疗法有反应。PAV疗法应用于可手术病例时，带来了出色的5年生存率，Ia期高达100%，Ib期为92.9%，II期为53.1%，Ib + II期为66.9%。一项对Ib期和II期病例进行的约4年的关于贝司他汀的随机对照研究表明，与对照组相比，贝司他汀治疗组的无病率和生存率均显著更高。
